Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...

Eversource's strategic focus includes divesting non-core assets, strengthening its balance sheet, and projecting 5%-7% EPS ...

Benchmark indices Nifty and Sensex are managing to hold on to modest gains in the afternoon session on March 25, as some ...

Benchmark indices Nifty and Sensex traded marginally higher on March 25, thanks to support provided by IT stocks. However, ...

The DNA-testing company plans to sell its assets after the board rejected an acquisition proposal from Wojcicki.

In addition to this, Moody’s upgraded Merck & Co., Inc.’s senior unsecured revolving credit facility to Aa3 from A1, and the senior unsecured shelf ratings of both Merck & Co., Inc. and MSD ...

As of December 31, 2024, AnaptysBio had cash, cash equivalents, and investments greater than $420 million and anticipates ...

The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious ...

Celadon Pharmaceuticals is set to delist from London's AIM after its directors resigned. The medical cannabis firm on Monday said that it will propose to move ahead with the cancellation of trading of ...

Cardinal Health outpaces S&P 500 with strong growth in specialty pharmaceuticals. Read why CAH stock has limited upside ...